

# 1 Epidemiological and clinical characteristics of COVID-19 in

## 2 adolescents and young adults

3 Jiaqiang Liao, Ph.D.<sup>1#</sup>, Shibing Fan, MD.<sup>2,3#</sup>, Jing Chen, BD.<sup>2,3#</sup>, Jianglin Wu,  
 4 BD.<sup>2,3#</sup>, Shunqing Xu, Ph.D.<sup>1</sup>, Yuming Guo, Ph.D.<sup>4,5,6</sup>, Chunhui Li, Ph.D.<sup>1</sup>, Xianxiang  
 5 Zhang, BD.<sup>2,3</sup>, Chuansha Wu, Ph.D.<sup>1</sup>, Huaming Mou, Ph.D.<sup>2,3</sup>, Chenxi Song, BD.<sup>7</sup>,  
 6 Feng Li, BD.<sup>2,3</sup>, Guicheng Wu, MD.<sup>2,3</sup>, Jingjing Zhang, Ph.D.<sup>1</sup>, Lian Guo, MD.<sup>2,3</sup>,  
 7 Huawen Liu, Ph.D.<sup>2,3</sup>, Jinglong Lv, MD.<sup>2,3</sup>, Lixin Xu BD.<sup>2,3\*</sup>, Chunhui Lang, Ph.D.<sup>2,3\*</sup>

8

9 <sup>1</sup>School of Public Health, Tongji Medical College, Huazhong University of Science  
 10 and Technology, Wuhan, Hubei, People's Republic of China.

11 <sup>2</sup>Department of Clinical Nutrition, Chongqing University Three Gorges Hospital

12 <sup>3</sup>Department of Clinical Nutrition, Chongqing Three Gorges Central Hospital.

13 <sup>4</sup>School of Public Health and Management, Binzhou Medical University, Yantai,  
 14 Shandong, China.

15 <sup>5</sup> Department of Epidemiology and Biostatistics, School of Public Health, Zhengzhou  
 16 University, Zhengzhou, China.

17 <sup>6</sup>Department of Epidemiology and Preventive Medicine, School of Public Health and  
 18 Preventive Medicine, Monash University, Melbourne, Australia.

19 <sup>7</sup>Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of  
 20 Medical Sciences and Peking Union Medical College, A 167, Beilishi Road, Xicheng  
 21 District, Beijing, 100037, China.

22 <sup>#</sup> The authors are contributed equally to this article.

23

24 \* Corresponding author: Dr. Jiaqiang Liao (Email: [ljq19861023@163.com](mailto:ljq19861023@163.com)). School of  
 25 Public Health, Tongji Medical College, Huazhong University of Science and  
 26 Technology, Wuhan 430030, People's Republic of China; Dr. Mr. Lixin Xu (Email:  
 27 [cqsxzxykywsb@163.com](mailto:cqsxzxykywsb@163.com)). Department of Clinical Nutrition, Chongqing Three  
 28 Gorges Central Hospital. Chongqing Three Gorges Central Hospital 404000, NO.165  
 29 Xincheng Road, Wanzhou, Chongqing, People's Republic of China; Dr. Chunhui  
 30 Lang (Email: [langchunhui87@163.com](mailto:langchunhui87@163.com)). Department of Clinical Nutrition,  
 31 Chongqing Three Gorges Central Hospital. Department of Clinical Nutrition,  
 32 Chongqing Three Gorges Central Hospital 404000, NO.165 Xincheng Road,  
 33 Wanzhou, Chongqing, People's Republic of China.

34

35

36

37

38

39

40

41

42

43

## 44 ***Abstract***

45 **Background:** Adolescents and young adults might play a key role in the worldwide  
46 spread of Coronavirus Disease 2019 (COVID-19), because they are more involved in  
47 overseas studying, business, working, and travelling. However, the epidemiological  
48 and clinical characteristics of them are still unknown.

49 **Methods:** We collected data of 46 confirmed COVID-19 patients aged 10 to 35 years  
50 from the study hospital. The demographics, epidemiological, and clinical data were  
51 collected. Several key epidemiological parameters, the asymptomatic cases and  
52 transmission to their family members and the clinical characteristics at admission, and  
53 during treatment were summarized.

54 **RESULTS:** Of 46 confirmed patients, 14 patients (47.3%) were aged from 10 to 24  
55 years, and 24 (52.7%) patients were male. The mean incubation period for  
56 symptomatic cases was 6.6 days (95% confidence interval (CI) 4.4 - 9.6). The median  
57 serial interval was 1.9 days (95% CI 0.4 - 6.2). Three of asymptomatic cases showed  
58 the transmission to their family members. Only 1 patient was identified as severe  
59 cases at admission. The common symptoms at admission were dry cough (34, 91.0%),  
60 and fever (29, 69.0%). Nearly 60% of the patients had showed ground-glass opacity  
61 by chest CT findings. Three patients developed acute kidney injury during treatment.  
62 Majority of patients (78.3%) were discharged by the end of the follow-up.

63 **Conclusions:**

64 The adolescent and young adult patients of COVID-19 had a long incubation period,  
65 and a short serial interval. The transmission to their family contactors occurred in  
66 asymptomatic cases. Few of the study patients have developed complications during  
67 treatment.

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

## 85 Introduction

86 The coronavirus disease (COVID-19), a newly emerging infectious pneumonia with  
 87 unknown causes, was originated in Wuhan, Hubei Province, China since December,  
 88 2019. Since its special onset time (during the Chinese spring festival), the incidences  
 89 of COVID-19 were rapidly reported across China<sup>1</sup>. Early epidemiological and clinical  
 90 studies depicted that the majority of the patients were middle-aged, or elder  
 91 individuals, with a mean incubation period of 5.2 days (range 0-14 days), and a serial  
 92 interval of 7.5 days (95% CI 2-17 days)<sup>2-4</sup>. The most common symptoms were fever,  
 93 cough, and fatigue<sup>3-5</sup>. Most of the patients presented the abnormalities of chest  
 94 CT-findings such as ground-glass opacity, and bilateral patchy shadowing<sup>4-6</sup>. The  
 95 patients aged above 65 years were more likely to be severe cases and developed  
 96 severe acute complications such as pneumonia, Acute Respiratory Distress Syndrome  
 97 (ARDS), shock, and acute cardiac injury during treatment<sup>3-5</sup>. These studies provided  
 98 essential evidence to guide the early medical screen, diagnosis of COVID-19 cases,  
 99 isolating of the suspected individuals, and clinical treatments. However, with the rapid  
 100 progress of COVID-19, many new characteristics have emerged, which need update  
 101 more evidence. The most important point is that there has been increasing younger  
 102 patients were confirmed across China. One study from Chinese Center for Disease  
 103 Control and Prevention indicated that 4168 (9%) of the patients through February 11,  
 104 2020 were aged younger than 30 years<sup>7</sup>. In addition, outbreaks of COVID-19 were  
 105 reported worldwide. It is suspected that their first-generation cases were imported

106 from China<sup>8-10</sup>. Several countries, such as South Korea, Japan, and Italy are  
 107 experiencing a sharp increase in incident COVID-19 confirmed cases. Younger  
 108 individuals were more likely to be carriers of COVID-19 across counties, since they  
 109 were more likely involved in overseas study, business, work and travel. For example,  
 110 in South Korea, 178 out of 431 confirmed cases, which were publicly announced in  
 111 the website of Ministry of Health and Welfare, were aged  $\leq 35$  years through March  
 112 1, 2020<sup>11</sup>. However, as far as we know, no study has been specifically conducted to  
 113 research the epidemiological and clinical characteristics in younger patients of  
 114 COVID-19. It is an essential step to prevent the worldwide epidemic of COVID-19 in  
 115 the future.

116

117 In this study, basing on a retrospective case series data, we aimed to estimate the key  
 118 epidemiological characteristics and describe the clinical symptoms, treatments, and  
 119 hospital outcomes for COVID-19 patients in adolescents and young adults.

120

## 121 **Methods**

### 122 **Study Design and Participants**

123 In this study, we defined the adolescent as 10-24 years of age and young adult as  
 124 25-35 years of age according to the World Health Organization's definition. We  
 125 retrospectively reviewed the medical records of confirmed COVID-19 cases aged

126 from 10 to 35 years who were hospitalized in Chongqing Three Gorges Central

127 Hospital of Chongqing University from January 25, 2020 to February 18, 2020.

128

## 129 **Data Collection**

130 Epidemiological data were collected using standardized questionnaire through

131 face-to-face or telephone interviewing with patients or their family members. We

132 firstly collected the demographic and social-economic information such as height and

133 weight, educational level, and behavioral characteristics such as smoking, alcohol

134 consumption, and physical activities. Then, we investigated the exposure date and

135 types for each patient during the 1 month before the date of symptoms onset. For

136 those who resided in Wuhan, we further collected the histories of exposing to the

137 Huanan Seafood wholesale market or other similar market. We collected the earliest

138 date of symptoms onset and the specific symptoms. For those who were the first case

139 of developing symptoms out of family (index patients), we further interviewed their

140 family contactors with exposure histories with index patient, date of symptoms onset,

141 date of medical visit, and date of confirmation. The clinical information for

142 confirmed cases were abstracted from medical records. We collected several key

143 information of date including date of clinical symptoms onset, date of primary visit to

144 health facilities, and date of confirmation. The typical clinical symptoms and the data

145 of chest CT scan for each case were collected at the admission and during the

146 treatment. The medical histories and treatments such as antiviral therapy,

147 antimicrobial therapy, corticosteroid therapy, and respiratory support were  
148 simultaneously recorded. We further collected the data of complications for cases  
149 during treatment. The ARDS was defined as the interim guidance of WHO for novel  
150 coronavirus, and acute kidney injury was defined on the basis of the highest serum  
151 creatinine level or urine output criteria according to the kidney disease improving  
152 global outcomes classification<sup>12 13</sup>. Cardiac injury was defined if the serum levels of  
153 cardiac biomarkers (eg, troponin I) were above the 99th percentile upper reference  
154 limit or new abnormalities were shown in electrocardiography and echocardiography.  
155 The clinical outcomes (discharge, still treatment, or death) were consistently observed  
156 until the date of February 23, 2020. The epidemiological data were inputted by  
157 Epidata with double checking. To ensure the accuracy of the clinical data, Two  
158 researchers also independently reviewed the electronic medical records.

#### 159 **Laboratory confirmation and tests**

160 The criteria of diagnosis for COVID-19 cases was based on national recommendation  
161 of the New Coronavirus Pneumonia Prevention and Control Program (6<sup>th</sup> edition)<sup>14</sup>.  
162 Briefly, the throat swab samples or lower respiratory tract were collected and  
163 processed at the department of clinical laboratory of study hospital. Then, the  
164 2019-nCoV RNA were extracted from the patients who were suspected of having  
165 2019-nCoV infection. Finally, the throat swabs were placed into a collection tube with  
166 150  $\mu$ L of virus preservation solution, and total RNA was extracted within 2 hours  
167 using there spiratory sample RNA isolation kit (Suzhou Tianlong Biotechnology Co.



168 Ltd , Roche's COBASZ480). A Reverse Transcription-Polymerase Chain Reaction  
169 (RT-PCR) assay with a cycle threshold value (Ct-value) less than 37 was defined as a  
170 positive test result. Asymptomatic cases were defined as those who presented positive  
171 results by conducting the nucleic acid test of COVID-19, and had no elevated  
172 temperature measured or self-reported fever and no gastrointestinal or respiratory  
173 symptoms such as cough and sore reported by physicians at admission. To confirm  
174 the validity, we further conducted a face-to face or telephone interview to collect  
175 information of symptoms before 2 weeks of admission for each asymptomatic case.  
176 For each patient, the laboratory tests were performed at admission, which included  
177 routine blood tests, serum biochemistry, and coagulation function.

178

## 179 **Statistical analysis**

180 We described the differences of demographic factors, symptoms at admission,  
181 comorbidities, and chest CT findings (10-24y, and 25-35y). We summarized the  
182 distribution of laboratory findings for cases using median and interquartile range  
183 among groups of total cases, 10-24y, and 25-35y. We defined the incubation period as  
184 the time interval from the date of exposure to the date of symptoms onset. We  
185 included two types of patients who could recalled the exact date of travelling to  
186 Wuhan or contacting with other confirmed cases. To ensure the accuracy, those who  
187 have reported more than one exposure sources or contacting periods over 3 days were  
188 excluded. We used a parametric survival analysis model with Weibull distribution to

189 estimate the distribution of incubation period. Since the asymptomatic cases at first  
190 medical visit could develop symptoms during the follow up, we firstly treated the  
191 incubation period for asymptomatic cases as right-censored data (from the date of  
192 exposure to the date of first medical visit) and performed the estimations. Then, we  
193 excluded the asymptomatic cases and repeated the estimations. We defined the family  
194 clustered events as those who were the first cases of developing symptoms in their  
195 family (index patient), and their family members (secondary cases) had a clear contact  
196 history to the index patient and had no other potential infection source. We used the  
197 date of symptoms onset to measure the date of illness onset. We defined the serial  
198 interval as the time interval from the dates of illness onset between index case and the  
199 secondary cases. We used a parametric survival analysis model with gamma  
200 distribution to estimate the distribution of serial interval. We further calculated the  
201 time interval from the date of symptoms onset to the date of first medical visit using  
202 parametric survival model with Weibull distribution. We finally compared the  
203 differences of treatments, days of persisting fever during treatment, days of  
204 transforming to negative results by COVID-19 nucleic acid tests into negative during  
205 treatment, and prognosis outcomes by different age groups.  
206  
207 We performed the summaries and significance tests by SAS 9.4, The parametric  
208 survival analyses were conducted by R 3.1.1, The statistically significant level was  
209 defined as 0.05 with a 2-side test.

## 210 **Ethical approval:**

211 Data collection and analyses of cases were approved by the institutional ethnic board  
212 of three gorges hospital affiliated of Chongqing University (No.2020-7(论)).  
213 Since the epidemiological interview for the study cases is a part of a continuing public  
214 health outbreak investigation determined by the National Health Commission of the  
215 People's Republic of China and the identified information was deleted. The individual  
216 consent was exempted.

217

## 218 **Results**

219 We totally included 46 hospital diagnosed COVID-19 patients (Table 1). Majority  
220 of them were young adults (n=32), and the rest were adolescents (n=14). The main  
221 exposure types of patients included contacting with other confirmed cases (22,47.8%)  
222 or residing in Wuhan (19, 41.3%). Compared with young adult, adolescent was more  
223 likely to reside or travel to Wuhan. Half of the patient were men (24, 52.2%), had a  
224 normal BMI (24, 52.2%), and never conducted physical activity (23, 50.0%).  
225 Compared with young adult, adolescent was less likely to be overweight/obesity,  
226 smoking, never conducting physical activity, and never drinking alcohol. Few of  
227 patients had 1 or more medical disease histories (6, 13.0%). The specific medical  
228 diseases included obesity (1), diabetes (1), Chronic obstructive pulmonary disease (1),  
229 hyperthyroidism (1), kidney stones (1), and arthrolithiasis (1). Only one (2.2%)  
230 patient was severe case, and 4 (8.7%) were asymptomatic at admission. The most

231 common symptoms at admission were dry cough (34, 81.0%), fever (29, 69.1%), and  
 232 expectoration (16, 38.1%). The less common symptoms included headache, fatigue,  
 233 pharyngalgia, chest pain, anorexia, myalgia, dizziness, diarrhea, nausea, and shortness  
 234 of breath. The common pathological changes of chest CT findings were ground-glass  
 235 opacity (29, 63.0%), and bilateral patchy shadowing (12, 26.1%). Compared with  
 236 young adults, no severe cases and higher odds of asymptomatic cases (14.3% vs  
 237 6.3%) were observed in adolescent patients. Fewer adolescent patients reported fever,  
 238 headache, and fatigue at onset illness. Only 7 (50.0%) of adolescent patients showed  
 239 ground-glass opacity for chest CT scanning, compared with 22 (68.8%) of that in  
 240 young adult. We displayed the typical patterns of chest CT scan for adolescents and  
 241 young adults in Figure 1.

242

243 We recorded family clustered events from 6 symptomatic cases at admission (Figure  
 244 2). Among 14 patients who provided exact date of travelling to Wuhan or contacting  
 245 with other confirmed cases, the estimated median incubation period was 8.3 days (95%  
 246 CI 5.0 -13.4) (Figure 3 Panel A). The estimated 95<sup>th</sup> percentile of incubation period  
 247 could reach as long as 24.8 days (95% CI 14.9 - 47.6). After excluding 3  
 248 asymptomatic cases, the estimated median incubation period decreased to 6.6 days  
 249 (95% CI 4.4 - 9.6) (Figure 3 Panel B). The estimated 95<sup>th</sup> percentile of incubation  
 250 period decreased to 14.8 days (95% CI 10.4 - 22.0). According to the definition of  
 251 serial interval, we only included 12 secondary cases who provided exact dates of

252 illness onset from 6 families with symptomatic index cases to estimate the distribution  
253 of serial interval (Figure 3 Panel C). The estimated median serial interval was 1.9  
254 days (95% CI 0.4 - 6.2). The estimated 95<sup>th</sup> percentile of serial interval could reach as  
255 long as 28.6 days (95% CI 10.6 -76.9). Based on 42 symptomatic cases, we estimated  
256 the median days from symptom onset to first medical visit to be 1.4 days (95% CI 0.8  
257 - 2.4) (Figure 3 Panel D). The estimated 95<sup>th</sup> percentile days from symptom onset to  
258 first medical visit was 13.2 days (95% CI 8.3 - 20.9).

259  
260 On admission, 10 (21.7%) patients were leucopenia (white blood cell count  $< 4 \times$   
261  $10^9/L$ ), and 29 (63.0%) patients were lymphopenia (Table 2). Ten patients (21.7%)  
262 had decreased levels of platelet count ( $< 150 \times 10^9/L$ ). The other elevated levels of  
263 laboratory indicators for study patients were lactate dehydrogenase (9, 19.6%),  
264 C-reactive protein (9, 19.6%), D-dimer levels (7, 15.2%), alanine aminotransferase (7,  
265 15.2%), and total bilirubin (7, 15.2%). Numerous differences were observed in  
266 laboratory findings between adolescent and young adult patients. For example, 8  
267 (25.0%) young adult patients presented elevated levels of c-reactive protein, while  
268 only 1 adolescent patient showed the similar pattern.

269  
270 The treatments and prognosis outcomes were summarized in Table 3. During the  
271 treatment periods, all patients received antiviral therapy, 39 (84.8%) patients received  
272 oxygen inhalation, and 43 (93.5%) patients received interferon alpha inhalation. Few

273 patients (5, 10.9%) received antifungal treatment. Three (6.5%) patients have  
 274 developed acute kidney injury during the treatment. The estimated median days from  
 275 the date of admission to the date of consecutively negative results for COVID-19  
 276 nucleic acid tests were 12.6 days (95% CI 11.2 - 14.1). The median days of persistent  
 277 fever during admission were 5 days (IQR 1- 8). Until the date of 25<sup>th</sup> February 2020,  
 278 36 patients had been discharged, 10 patients were hospitalized, and no patients were  
 279 died. Compared with young adult, adolescent patients received less therapy of oxygen  
 280 inhalation and had shorter days of persistent fever.

281

282 We observed 4 asymptomatic cases at admission and both of them were consistently  
 283 confirmed as asymptomatic cases by our face-to-face or telephone interviews. Their  
 284 progresses of COVID-19 during treatment periods were shown in Figure 4. Two  
 285 asymptomatic cases (case 2 and case 3) still did not show any symptoms until  
 286 February 23, 2020. Asymptomatic case 1 have developed symptoms of shortness of  
 287 breath, difficulty breathing, and chest tightness in 17 days after admission.

288 Asymptomatic case 4 have developed symptoms of dry cough, phlegm, and nausea in  
 289 6 days after admission and his COVID-19 nucleic acid have transformed into negative  
 290 in 14 days after admission. We detected family-clustered events from 3 asymptomatic  
 291 cases, which indicated that the transmission during their asymptomatic periods  
 292 occurred between asymptomatic cases and their family close contactors. For example,

two relatives of the asymptomatic case 1 who lived with him, and did not report other potential transmission sources, have developed illness in January 17, 2020.

## Discussion

This study, to the best of our knowledge, is the first to assess the epidemiological and clinical characteristics of COVID-19 in adolescent and young adult patients. We added new knowledge to deeply understand the characteristics of COVID-19 distributed in different sub-populations. We detected 4 asymptomatic cases out of 46 patients at admission. We reported a mean incubation period of 7.2 days in symptomatic cases, and could reach as long as 10 days with allowing for the truncated time periods of asymptomatic cases. We estimated a median serial interval of 1.9 days from the dates of illness onset in index patients to the date of developing illness in their family close contactors. We found that the most common symptoms were dry cough, fever, and expectoration. Only 29 (63.0%) of the patients showed the ground-glass opacity by chest CT scan. The typical changes of laboratory indicators were decreased white blood cell count, decreased lymphocyte count, decreased platelet count, increased lactate dehydrogenase, and elevated C-reactive protein. During the treatment, we found only 3 patients occurred acute kidney injury, and no other medical complications were reported. Nearly 80% of the patients were discharged in the end of follow-up.

314 The incubation period of COVID-19 in adolescent and young adult is longer than the  
315 elder patients. A retrospective study reported the mean incubation period was 5.2 days  
316 (95% CI: 4.1-7.0) and the 95<sup>th</sup> percentile of incubation period was 12.5 days based on  
317 early COVID-19 patients from Wuhan <sup>2</sup>. A later study, which used the data of  
318 travelers from Wuhan, estimated the mean incubation period to be 6.4 days (95% CI  
319 5.6-7.7) and ranged from 2.2 to 11.1 days<sup>15</sup>. The similar studies reported a shorter  
320 incubation period (median = 4 days) for patients outside Wuhan<sup>6 16</sup>. However, most of  
321 these studies were based on the patients aged over 50 years. Knowledge gaps still  
322 persisted for the incubation period in younger COVID-19 patients.. In this study, we  
323 used patients with exact information for exposure time intervals and reported a mean  
324 incubation period of 7.2 days (95% CI 5.2-10.1) for patients aged under 35 years. The  
325 95<sup>th</sup> percentile of incubation period was 14.8 days (95% CI 10.4-22.00). With  
326 allowing for the right truncated periods for asymptomatic cases, the estimated  
327 incubation period (95<sup>th</sup> percentile) could reach as long as 24.8 days (95% CI 14.9 -  
328 47.6). Our findings highlighted the importance of extending the medical observing or  
329 quarantining time periods for adolescents and young adult of COVID-19 patients.

330

331 Our study suggests that the person-to-person transmission have occurred rapidly from  
332 adolescent and young adult infected cases of COVID-19 to their family contactors.

333 We recorded 6 family-cluster events of COVID-19 in asymptomatic patients. We  
334 estimated the mean serial interval to be 6.5 days (95% CI 2.5 -17.4), which is shorter



335 than that (7.5 days, 95% CI 5.3-19.0) estimated from early Wuhan patients<sup>2</sup>. Most  
 336 importantly, we estimated the median serial interval to be 1.9 days (95% CI 0.4 - 6.2),  
 337 which was still lower than that (4.0 days, 95% CI 3.1-4.9) estimated in a recent  
 338 modeling study<sup>17</sup>.

339  
 340 We provided evidence linking cluster-transmission to adolescent and young adult  
 341 asymptomatic patients of COVID-19. In this study, four out of 46 patients were  
 342 identified as asymptomatic cases. Three of them were identified as the primary cases  
 343 for their contacting family members. Two asymptomatic primary cases were still  
 344 show neither any symptoms nor chest CT findings during treatment. One  
 345 asymptomatic primary case has suffered with difficulty and shortness of breath, and  
 346 chest tightness during 17 days after treatment. However, all of their family close  
 347 contactors have developed symptoms before the admission date of asymptomatic  
 348 cases. Our findings were consistent with the existing evidence. Camilla Rothe et al.  
 349 firstly reported an asymptomatic Chinese woman might be the transmission source for  
 350 her two Germany business partners<sup>18</sup>. Zhen-Dong Tong et al. reported a 2-family  
 351 cluster of COVID-19 patients in Zhejiang Province after each family's primary case  
 352 contacted with an asymptomatic case of COVID-19 from Wuhan<sup>19</sup>. Recently, a  
 353 similar study has identified a 20-years age Chinese woman as an asymptomatic carrier  
 354 who have infected her five family members<sup>20</sup>.

355

356 Compared with the early evidence from Wuhan patients, the adolescent and young  
357 adult patients of COVID-19 presented different patterns of symptoms and fewer  
358 abnormalities of laboratory indicators at admission. The most common symptoms  
359 were fever (83%), cough (82%), and shortness of breath (31%) in early elder patients  
360 from Wuhan<sup>3</sup>. Later studies with more case series reported other common symptoms  
361 including fatigue, gastrointestinal symptoms, upper airway congestion, myalgia, and  
362 headache<sup>4 6 21</sup>. The results of chest CT scanning indicated that nearly 80% of the  
363 early patients showed bilateral pneumonia, and ground glass opacity<sup>3 4 21 22</sup>.  
364 Laboratory examinations indicated that over 70% of the patients emerged  
365 lymphocytopenia, elevated lactate dehydrogenase, and elevated C reactive protein<sup>3 4 23</sup>.  
366 In this study, most common symptoms at admission were dry cough (81.0%), fever  
367 (69.1%), and expectoration (38.1%). Only 1 patients reported shortness of breath at  
368 admission. The proportion of reporting fever at admission decreased to 58.3% in  
369 adolescent patients. Nearly 60% of the patients showed ground-glass opacity changes  
370 by chest CT findings, which decreased to 50% in adolescent patients. Only 26.09%  
371 and 13.04% of all patients showed the bilateral patchy shadowing or consolidation by  
372 chest CT findings. By laboratory examinations, 63.0% of the patients had  
373 lymphocytopenia, which was close to the existing evidence. However, only a few  
374 patients had elevated levels of lactate dehydrogenase (19.6%), and C-reactive protein  
375 (19.6%). Both of these abnormalities of laboratory findings were less pronounced in  
376 adolescent patients.

377

378 Our study indicated that younger patients have better prognosis outcomes during the  
379 treatment.

380 Early studies reported that the nearly 40% of the patients have at least one medical  
381 chronic disease at admission and the common complications during the treatment  
382 included acute respiratory distress syndrome, shock, acute cardiac injury, arrhythmia,  
383 kidney injury, and liver dysfunction<sup>3 4 6 24</sup>. Most of the patients received antiviral  
384 therapy, and oxygen inhalation. Part of them received glucocorticoid therapy, or  
385 antifungal treatment. Nearly 20% of the patients were identified as severe cases and  
386 received mechanical ventilation and Extracorporeal Membrane Oxygenation (ECMO).  
387 In our study, only 1 (2.2%) patients were identified as severe cases at admission.  
388 After received antiviral therapy, interferon alpha inhalation, and oxygen inhalation,  
389 nearly 80% of the patients discharged at the end of the follow-up. Three patients  
390 developed severe kidney injury during treatment.

391

392 This study provided the initial evidence for the epidemiological and clinical  
393 characteristics of COVID-19 in adolescent and young adult. The longer incubation  
394 period indicated that longer time periods of medical observation and isolation are  
395 needed for suspected younger patients. The shorter serial interval indicated that the  
396 transmission could emerged rapidly between younger patients and their family  
397 members or close contactors. Compared with elder patients, younger patients had

fewer typical signs and symptoms, and less abnormalities of laboratory findings.

Fewer of them developed severe complications during treatment. Both of these evidence indicated that the adolescent and young adult might be the key subpopulation in the later stage for preventing the worldwide spread of COVID-19.

The study has some limitations. Firstly, we conducted this study only based on 46 patients, which enabled us to compare the epidemiological and clinical differences between adolescent and younger adult with significance tests. Our results needed to be replicated with large sample size. Secondly, at the end date of this study, nearly 20% of the patients still hospitalized, which limited us to fully illuminate the prognosis outcomes for the study patients.

## Conclusions

Compared with elderly patients, the adolescent and young adult COVID-19 patients had a longer incubation period, a shorter serial interval, and a higher odd to be asymptomatic. The transmission to their family close contactors occurred in several asymptomatic cases. Few of the study patients have developed complications during treatment.

## Competing interests:

All authors declare no competing interests.

419    **Acknowledgment**

420    We thank all the patients in the study and Huilin Liu, Feifei Yuan, Fang Yang, Xia  
421    Huang, Yingchun Jiang, Bangjuan Yu, Runze Deng, and Li Chen for their kindly help  
422    for data collection in the study hospital. This work was supported by the Fundamental  
423    Research Funds for the Central Universities (No.2020CDJYGRH-YJ03).

424

425

## 426     **References**

- 427     1. National Health Commission of the People's Republic of China home page
- 428         [Available from: (<http://www.nhc.gov.cn>)].
- 429     2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of
- 430         Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020 doi:
- 431         10.1056/NEJMoa2001316 [published Online First: 2020/01/30]
- 432     3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
- 433         cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
- 434         study. *Lancet* 2020;395(10223):507-13. doi: 10.1016/s0140-6736(20)30211-7
- 435         [published Online First: 2020/02/03]
- 436     4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients
- 437         With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*
- 438         2020 doi: 10.1001/jama.2020.1585
- 439     5. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
- 440         2019 in China. *New England Journal of Medicine* 2020 doi:
- 441         10.1056/NEJMoa2002032
- 442     6. Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients
- 443         infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan,
- 444         China: retrospective case series. *BMJ* 2020;368:m606. doi: 10.1136/bmj.m606

- 445 7. Team TNCPERE. The Epidemiological Characteristics of an Outbreak of 2019  
446 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly*  
447 2020;2:113.
- 448 8. Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 Infection in  
449 Returning Travelers from Wuhan, China. *New England Journal of Medicine* 2020  
450 doi: 10.1056/NEJMc2001899
- 451 9. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in  
452 the United States. *New England Journal of Medicine* 2020 doi:  
453 10.1056/NEJMoA2001191
- 454 10. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human  
455 Transmission of a Novel Coronavirus in Vietnam. *New England Journal of*  
456 *Medicine* 2020;382(9):872-74. doi: 10.1056/NEJMc2001272
- 457 11. Ministry of Health and Welfare home page [Available from:  
458 ([http://ncov.mohw.go.kr/index\\_main.jsp](http://ncov.mohw.go.kr/index_main.jsp))].
- 459 12. WHO. Novel coronavirus – China. Jan 12, 2020 [Available from:  
460 (<https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>)].
- 461 13. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work  
462 group. KDIGO clinical practice guideline for acute kidney injury. March, 2012.  
463 [Available from:  
464 ([https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-En](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf)  
465 [glish.pdf](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf))].

- 466 14. The National Institute for Viral Disease Control and Prevention Web Page  
467 [Available from: ([http://ivdc.chinacdc.cn/kyjz/202001/t20200121\\_211337.html](http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html))].
- 468 15. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel  
469 coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28  
470 January 2020. *Euro Surveill* 2020;25(5) doi:  
471 10.2807/1560-7917.Es.2020.25.5.2000062 [published Online First: 2020/02/13]
- 472 16. Ki M, nCo VT. Epidemiologic characteristics of early cases with 2019 novel  
473 coronavirus (2019-nCoV) disease in Republic of Korea. *Epidemiol Health*  
474 2020:e2020007. doi: 10.4178/epih.e2020007 [published Online First:  
475 2020/02/10]
- 476 17. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus  
477 (2019-nCoV) infections. *medRxiv* 2020:2020.02.03.20019497. doi:  
478 10.1101/2020.02.03.20019497
- 479 18. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection  
480 from an Asymptomatic Contact in Germany. *N Engl J Med* 2020 doi:  
481 10.1056/NEJMc2001468 [published Online First: 2020/02/01]
- 482 19. Tong ZD, Tang A, Li KF, et al. Potential Presymptomatic Transmission of  
483 SARS-CoV-2, Zhejiang Province, China, 2020. *Emerg Infect Dis* 2020;26(5) doi:  
484 10.3201/eid2605.200198 [published Online First: 2020/02/25]
- 485 20. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of  
486 COVID-19. *JAMA* 2020 doi: 10.1001/jama.2020.2565



- 487 21. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected  
488 with SARS-CoV-2 in Wuhan, China. *Allergy* 2020 doi: 10.1111/all.14238  
489 [published Online First: 2020/02/23]
- 490 22. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with  
491 COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet*  
492 *Infectious Diseases* 2020 doi: [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4)
- 493 23. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with  
494 2019 novel coronavirus pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*  
495 2020;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005 [published  
496 Online First: 2020/02/07]
- 497 24. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients  
498 with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,  
499 observational study. *Lancet Respir Med* 2020 doi:  
500 10.1016/s2213-2600(20)30079-5 [published Online First: 2020/02/28]  
501  
502

## 503 **Figure legends**

504 **Figure 1.** Chest computed tomographic (CT) images for study patients infected with  
505 COVID-19.

506 Panel A depicted the chest CT images for a patient aged 21 years on day 10 after  
507 illness onset, and Panel B depicted the chest CT images for a patient aged 33 years on  
508 day 14 after illness onset.

509

510 **Figure 2.** Information on exposures and dates of illness onset in 6 symptomatic cases  
511 and their family close contactors.

512 Numbers in boxes are calendar dates. Data from the 12 secondary cases (close  
513 contactors were defined as those who had clear exposure to only one index case and  
514 had no other potential source of infection) were used to estimate the distribution of  
515 serial interval.

516

517 **Figure 3.** Key distributions of epidemiological characteristics for study patients.

518 The estimated incubation period distribution for symptomatic cases and asymptomatic  
519 cases truncated at hospitalization is depicted in Panel A. The estimated incubation  
520 period distribution only for asymptomatic cases is depicted in Panel B. The estimated  
521 serial interval distribution is depicted in Panel C. The estimated distributions of times  
522 from illness onset to first medical visit is depicted in Panel D.

523

524 **Figure 4.** The progresses of clinical symptoms and lung CT findings during treatment

525 periods for 4 asymptomatic cases and their family contactors.

526 Numbers in boxes are calendar dates. The symptoms and the chest CT-findings

527 related to COVID-19 were marked in onset dates by black arrows.

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

## 545 Tables

546 **Table 1.** Baseline characteristics of study patients infected with COVID-19.

Characteristics	No. (%)		
	Total (N=46)	Adolescents (n=14)	Young adults (n=32)
Exposure types			
Resided in Wuhan	19 (41.3)	7 (50.0)	12 (37.5)
Travel to Wuhan	3 (6.5)	2 (14.3)	1 (3.1)
Contact with confirmed cases	22 (47.8)	5 (35.7)	17 (53.1)
No experiences	2 (4.4)	0 (0.0)	2 (6.3)
Gender			
Male	24 (52.2)	7 (50.0)	17 (53.1)
Female	22 (47.8)	7 (50.0)	15 (46.9)
Education, years			
1-9	18 (39.1)	6 (42.9)	12 (37.5)
10-12	10 (21.7)	3 (21.4)	7 (21.9)
≥13	18 (39.1)	5 (35.7)	13 (40.6)
BMI, kg/m <sup>2</sup>			
Under weight	4 (8.7)	1 (7.1)	3 (9.4)
Normal	24 (52.2)	8 (57.1)	16 (50.0)
Overweight/obesity	17 (37.0)	4 (28.6)	13 (40.6)

#### Smoke status

Never	41 (89.1)	13 (92.9)	28 (87.5)
Ever or now	5 (10.9)	1 (7.1)	4 (12.5)

#### Physical activity

Never	23 (50.0)	6 (42.9)	17 (53.1)
Rare	14 (30.4)	3 (21.4)	11 (34.4)
Often	9 (19.6)	5 (35.7)	4 (12.5)

#### Alcohol consumption

Never	32 (71.1)	11 (78.6)	21 (67.7)
Rare or often	13 (28.9)	3 (21.4)	10 (32.3)

#### Chronic diseases history

None	40 (87.0)	13 (92.9)	27 (84.4)
At least one <sup>a</sup>	6 (13.0)	1 (7.1)	5 (15.6)

#### Severity

Asymptomatic	4 (8.7)	2 (14.3)	2 (6.3)
Mild	41 (89.1)	12 (85.7)	29 (90.6)
Severe	1 (2.2)	0 (0.0)	1 (3.1)

#### Symptoms at administration

Dry cough	34 (81.0)	11 (91.7)	23 (76.7)
Fever	29 (69.1)	7 (58.3)	22 (73.3)
Expectoration	16 (38.1)	6 (50.0)	10 (33.3)

Headache	8 (19.1)	2 (16.7)	6 (20.0)
Fatigue	8 (19.1)	2 (16.7)	6 (20.0)
Pharyngalgia	7 (16.7)	3 (25.0)	4 (13.3)
Chest pain	3 (7.1)	1 (8.3)	2 (6.7)
Chest stuffiness	3 (7.1)	2 (16.7)	1 (3.3)
Anorexia	4 (9.5)	0 (0.0)	4 (13.3)
Myalgia	3 (7.1)	1 (8.3)	2 (6.7)
Dizziness	3 (7.1)	2 (16.7)	1 (3.3)
Diarrhea	2 (4.8)	2 (16.7)	0 (0.0)
Nausea	1 (2.4)	0 (0.0)	1 (3.3)
Rhinobyon	1 (2.4)	0 (0.0)	1 (3.3)
Shortness of breath	2 (2.4)	0 (0.0)	2 (6.7)
Erythra	1 (2.4)	1 (8.3)	0 (0.0)
CT findings for lung			
Ground-glass opacity	29 (63.0)	7 (50.0)	22 (68.8)
Bilateral patchy shadowing	12 (26.1)	5 (35.7)	7 (21.9)
Consolidation	6 (13.0)	2 (14.3)	4 (12.5)
Local patchy shadowing	2 (4.4)	0 (0.0)	2 (6.3)

547

548 <sup>a</sup>The specific medical diseases included obesity (1), diabetes (1), Chronic lung  
549 disease (1), hyperthyroidism (1), kidney stones (1), and arthrolithiasis (1).

550 **Table 2.** Laboratory findings of study patients on admission. Values are  
551 medians (interquartile ranges) unless stated otherwise.

Variables	Total (N=46)	Adolescents (n=14)	Young adults (n=32)
White blood cell count ( $\times 10^9/L$ )	5.0 (4.1- 6.7)	5.4 (4.5- 6.7)	4.8 (3.9- 6.7)
<4 (No(%))	10.0 (21.74)	1.0 (7.1)	9 (28.1)
>10 (No(%))	2.0 (4.4)	0 (0.0)	2 (6.3)
Neutrophil count ( $\times 10^9/L$ )	3.4 (2.5- 4.4)	3.8 (3.1- 5.6)	3.2 (2.4- 4.4)
Lymphocyte count ( $\times 10^9/L$ )	1.3 (1.0- 1.8)	1.4 (1.1- 2.3)	1.3 (0.9- 1.8)
<1.5 (No(%))	29 (63.0)	8 (57.1)	21 (65.6)
Platelet count ( $\times 10^9/L$ )	192.5 (156.0- 237.0)	183 (156.0- 227.0)	194.5 (152.0- 248.0)
<150 (No(%))	10 (21.7)	2 (14.3)	8 (25.0)
Haemoglobin (g/L)	139.5 (130.0- 151.0)	147 (133.0- 151.0)	137.5 (128.5- 150.5)
Prothrombin time (S)	11 (10.6- 11.4)	11.25 (10.7- 11.9)	11 (10.5- 11.1)
Activated partial thromboplastin time (S)	27 (25.9- 30.3)	28.2(26.1- 30.4)	26.9 (25.0- 30.3)
D-dimer (mg/L)	0.3 (0.2- 0.4)	0.2 (0.1- 0.3)	0.3 (0.2- 0.4)
$\geq 0.5$ (No(%))	7 (15.2)	3 (21.4)	4 (12.5)
Alanine aminotransferase (U/L)	17.9 (11.6- 32.5)	16.3 (7.1- 24.3)	20 (11.7- 32.7)
>40 (No(%))	7 (15.2)	1 (7.2)	6 (18.8)
Aspartate aminotransferase (U/L)	18.3 (14.5- 26.9)	16.6 (12.4- 23.6)	19.3 (15.8- 28.6)
>40 (No(%))	3 (6.5)	0 (0.0)	3 (9.4)

Total bilirubin, $\mu\text{mol/L}$	8.7 (5.9- 14.6)	9 (5.9- 24.8)	8.3 (6.1- 13.5)
>17.1 (No(%))	7 (15.3)	4 (28.6)	3 (9.4)
Blood urea nitrogen, mmol/L	3.4 (2.6- 4.8)	3.9 (2.6- 4.9)	3.15 (2.6- 4.6)
Creatine ( $\mu\text{mol/L}$ )	61.5 (52.0- 79.0)	62.5 (53.0- 81.0)	61.5 (51.5- 77.0)
Creatine kinase (U/L):	57 (41.0- 73.0)	53 (42.0- 73.0)	57.6 (36.0- 74.9)
$\geq 200$ (No(%))	2 (4.4)	0 (0.0)	2 (6.3)
Lactate dehydrogenase (U/L):	195.5 (145.0- 240.0)	180 (152.0- 220.0)	200 (144.0- 244.0)
$\geq 250$ , (No(%))	9 (19.6)	2 (14.3)	7 (21.9)
Procalcitonin, ng/ml	0.03 (0.0- 0.1)	0.04 (0.0- 0.1)	0.03 (0.0- 0.1)
$\geq 0.1$ (No(%))	2 (4.4)	0 (0.0)	2 (6.3)
C-reactive protein, mg/L	2.6 (0.8- 9.4)	3.2 (0.3- 5.6)	3.0 (1.0- 10.0)
$\geq 10$ (No(%))	9 (19.6)	1 (7.1)	8 (25.0)

---

552

553

554

555

556

557

558

559

560



Table 3. Treatments and prognosis outcomes in patients with COVID-19.

Values are No. (%) unless stated otherwise.

Treatments and prognosis outcomes	Total patients (N=46)	Adolescents (N=14)	Young adults (N=32)
<b>Complications</b>			
Acute kidney injury	3 (6.5)	1 (7.1)	2 (6.3)
<b>Treatment</b>			
Antiviral therapy	46 (100.0)	14 (100.0)	32 (100.0)
Antifungal treatment	5 (10.9)	2 (14.3)	3 (9.4)
Oxygen inhalation	39 (84.8)	9 (64.3)	30 (93.8)
Atomization therapy			
Interferon alpha inhalation	43 (93.5)	13 (92.9)	30 (93.8)
N-acetylcysteine + interferon alpha inhalation	1 (2.2)	0 (0.0)	1 (3.1)
N-acetylcysteine + budesonide+interferon alpha inhalation	2 (4.4)	1 (7.1)	1 (3.1)
<b>Days of persistent fever during admission,</b>	5	4.5	5
<b>Median (IQR)</b>	(1.0-8.0)	(0.0-7.0)	(2.0-9.0)
<b>Days of transforming to negative of</b>	12.6	12.6	12.5



COVID-19 nucleic acid test after	(10.0-15.7)		
hospitalization, Median (95% CI) <sup>a</sup>	(11.2-14.1)		(10.9-14.4)

#### Prognosis


Hospital admission	10 (21.7)	2 (14.3)	8 (25.0)
Discharged	36 (78.3)	12 (85.7)	24 (75.0)

563 <sup>a</sup>Estimated using parametric survival analysis with Weibull distribution allowing  
564 for the patients who presented positive of COVID-19 and still hospitalized.  
565


A




B




### Cluster 1 (JANUARY 2020)





### Cluster 2 (JANUARY 2020)




### Cluster 3 (JANUARY 2020)




### Cluster 4 (JANUARY - FEBRUARY 2020)




### Cluster 4 (JANUARY - FEBRUARY 2020)







### Cluster 5 (JANUARY - FEBRUARY 2020)




### Cluster 6 (JANUARY - FEBRUARY 2020)






# JANUARY - FEBRUARY 2020


## Cluster 1



## Cluster 2



## Cluster 3



Resided In Wuhan

Contact With Confirmed Cases